Stocks / Stock overview

Astrazeneca PLC (AZN)

Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.

$178.79Price
-1.91%Day change
$277.29BMarket cap
2Our articles

NYSE · Price as of · Nasdaq Real Time Price

Stock Scorer
B62/100
  • Profitability20/20

    Profitable and growing: $6.56B net income over the last four reported quarters, up from $1.71B the year before.

  • Insider buying vs selling14/20

    Some insider buying (1 buy, $3,249) against larger selling (1 sell, $2.2M). Any open-market buying is worth noticing.

  • Dilution and offerings4/15

    2 offering-related filings in the last year (share-count history unavailable).

See the full breakdown
Analyst consensus
Buy$209.91
  • Analysts12
  • Implied upside+17.4%
  • Target range$158.00 to $240.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
AZN past month+6.4%
AZN closed at $179.70 on Nov 18, up 6.4% since Oct 20.$179.70$189.39$161.76Oct 20Nov 18
Close 20-day average 50-day average 200-day average

AZN closed at $179.70 on Nov 18, up 6.4% since Oct 20. Chart read: price above the 50-day moving average but below the 200-day; the 50-day is below the 200-day (downtrend structure); trading at 45% of the 52-week range ($155.62 to $209.48).

Congress trades in AZN

Source: STOCK Act disclosures filed with the House and SenateLatest disclosed

DateMemberActionAmount
2026-03-31Alan Armstrong OKPurchase$1,001 - $15,000
2026-03-30Alan Armstrong OKPurchase$15,001 - $50,000
All congress trades

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
6-KNovember 16, 2026BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU
6-KNovember 16, 2026IMFINZI + EV APPROVED IN US IN BLADDER CANCER
6-KNovember 16, 2026KLYGEFA (GEFURULIMAB) APPROVED IN THE US
6-KNovember 16, 2026KLYGEFA (GEFURULIMAB) APPROVED IN THE EU
4November 10, 2026PRIMARY DOCUMENT
6-KNovember 2, 2026ADMISSION OF FURTHER SECURITIES TO TRADING
6-KNovember 2, 2026TOTAL VOTING RIGHTS
6-KOctober 30, 20263RD QUARTER RESULTS
All SEC filings

Astrazeneca news

Tempus AI (TEM) gets a $200 million AstraZeneca commitment as the two extend their data deal through 2031
News

Tempus AI (TEM) gets a $200 million AstraZeneca commitment as the two extend their data deal through 2031

AstraZeneca made a $200 million fee commitment to Tempus AI under an amended deal covering 2027 through 2031, with at least $32 million a year. What happens if AstraZeneca spends less, and how the deal compares with Tempus's data sales.

Nov 18, 2026

Articles that mention Astrazeneca without it being the main subject.

Bristol Myers (BMY) leads Pathos AI's $237 million round; Tempus (TEM) to supply neurology data
News

Bristol Myers (BMY) leads Pathos AI's $237 million round; Tempus (TEM) to supply neurology data

Bristol Myers Squibb led the round and gets access to Pathos's AI platform for its drug research. Tempus will build a neurology dataset under a $55 million deal.

Oct 23, 2026

Frequently asked questions

What do analysts expect for AZN?

12 analysts cover Astrazeneca PLC (AZN). The consensus rating is Buy. The average price target is $209.91, in a range of $158.00 to $240.00.

Are insiders buying or selling AZN?

We have no qualifying Form 4 insider purchases or sales on record for Astrazeneca PLC (AZN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see AZN SEC filings?

Recent filings are listed on this page, newest first. The latest is a 6-K filed November 16, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.